Relief for Occasional Difficulty Falling Asleep

This block covers the medication's primary indication: the symptomatic relief of transient sleep disturbances or occasional sleeplessness in adults and adolescents. This medication is commonly used to help reduce difficulty in falling asleep. Gittalun is applied in contexts where short-term, supportive symptom management is appropriate, providing support that helps ease the overall symptom burden related to nocturnal alertness. The therapeutic use is relevant for easing difficulty with sleep onset, managing transient sleeplessness, and is applied in addressing situational restlessness before bed.

Primary Symptomatic Focus: Difficulty Falling Asleep

---

Management of Situational Restlessness

This section focuses on the symptomatic domains of excessive wakefulness and situational restlessness that oppose sleep onset. It is relevant in situations where symptoms stem from temporary functional strain or emotional tension (e.g., travel, minor life stress), contributing to easing the transition into a state of drowsiness and may assist with maintaining functional stability. Gittalun is relevant for managing symptoms that interfere with daily comfort during symptomatic periods. The therapeutic use supports the patient during difficult episodes by easing distress and promoting a state of drowsiness.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Map: Who can and cannot use Gittalun — official regulatory information

Eligibility scope	Official Regulatory Statements
Populations for whom use is allowed (as stated in label)	Adults (age 18 years and over) and Adolescents (age 12 years and over).
Populations for whom use is not recommended (if applicable)	Children under 12 years of age; women who are breastfeeding/nursing; and patients concurrently using Central Nervous System (CNS) depressants, including alcohol.
Populations for whom use is contraindicated	Patients with known hypersensitivity to doxylamine succinate, or those taking Monoamine Oxidase Inhibitors (MAOIs).
Age-related eligibility rules	Do not use in children under 12 years. Older adults (Geriatric) should use with caution due to potential increased sensitivity and anticholinergic effects.
Condition-specific eligibility rules	Use with caution in patients with: asthma or chronic breathing problems, narrow angle glaucoma, or obstructive conditions (e.g., stenosing peptic ulcer, urinary bladder-neck obstruction).
Pregnancy and lactation eligibility status (if explicitly documented)	Pregnancy: Self-medication requires consultation with a health professional. Lactation: Use is not recommended; a decision must be made to discontinue nursing or the drug.
Eligibility-related restrictions	Caution is recommended for patients with Hepatic Impairment and Renal Impairment due to the potential for reduced drug clearance.

---

Eligibility classifications (high-level)

Regulatory Classification	Official Regulatory Statements
Eligibility severity classification (as defined in official documents)	Contraindicated (MAOI use/hypersensitivity); Not Recommended (Children <12, Breastfeeding); Caution Recommended (Specific conditions, Organ impairment).
Regulatory basis (EMA / FDA / etc.)	Based on the anticholinergic and CNS depressant properties of the doxylamine molecule.
Eligibility-context constraints (as defined in official documents)	The presence of pre-existing obstructive disease (gastrointestinal or urinary) requires explicit caution.

---

Connection to the overall eligibility profile: Official regulatory documents define who can and cannot use Gittalun by establishing absolute exclusions based on concomitant MAOI use and hypersensitivity, setting a minimum age of 12 years, and specifying numerous conditional use restrictions. Eligibility is restricted for populations with respiratory, ocular, or obstructive medical conditions due to the drug’s anticholinergic action, which mandates consultation before use.

Interactions with other medicines and products

Regulatory documentation defines interaction constraints for Gittalun (Doxylamine succinate) based on pharmacodynamic and pharmacokinetic patterns.

Contraindicated and Restricted Combinations

Classification	Interacting Substance or Class	Regulatory Constraint
Contraindicated	Monoamine Oxidase Inhibitors (MAOIs)	Prohibited due to potential to prolong and intensify anticholinergic effects.
Avoid/Not Recommended	CNS Depressants (e.g., Alcohol, Opioid Analgesics, Hypnotic Sedatives)	May result in an additive pharmacodynamic effect, increasing the risk of severe drowsiness and central nervous system depression.
Avoid	Strong Cytochrome P-450 (CYP) Inhibitors	Use should be avoided due to the potential to increase Doxylamine plasma concentration by reducing metabolic clearance.

Other Documented Interaction Notes

Co-administration with other anticholinergic medications, such as tricyclic antidepressants, may enhance antimuscarinic actions. Administration timing is constrained regarding food intake: for formulations where absorption delay is a factor, the medication should be taken on an empty stomach to maintain the intended onset of effect. Official notes indicate that the elderly population may show increased sensitivity to the effects of the drug, which can alter the clinical significance of these documented interactions.

How Gittalun Works: Mechanism of Action

Primary Mechanism: Central Histamine H1 Receptor Blockade

Doxylamine, as a first-generation antihistamine, exerts its primary effect by acting as a competitive antagonist at the Histamine H1 receptors, primarily within the central nervous system (CNS). This molecular interaction suppresses the natural activity of the histaminergic arousal system, which is essential for maintaining wakefulness and alertness. By reducing the transmission of these excitatory signals, the mechanism contributes to the physiological state of reduced alertness.

Mechanism Cascade: Lipophilicity and CNS Depression

The molecule's high lipophilicity (fat solubility) is a key mechanistic property, enabling it to rapidly cross the blood-brain barrier to engage its central targets. This rapid access facilitates the resulting action, which is further augmented by Doxylamine's affinity for Muscarinic Acetylcholine Receptors. The combined antagonism of both the histaminergic and cholinergic pathways produces a generalized state of CNS depression, which is the core physiological consequence of the drug’s mechanism.

How to Use Gittalun: Administration Parameters

Gittalun is a single-ingredient medicine containing Doxylamine succinate and is administered via the oral route as a 25 mg tablet. Its usage is characterized by specific dosing, frequency, and duration for its short-term purpose. The standard dose for adults and adolescents 12 years of age and over is 25 mg (one tablet), which is taken once daily. This 25 mg amount is the maximum dose of the active ingredient in any 24-hour period.

---

The administration schedule involves taking the dose approximately 30 minutes before the intended time of going to bed to align the drug’s action with the onset of sleep. The tablet is to be swallowed whole with a glass of water, and intake may be managed with or without food. If a scheduled dose is missed, it is not to be taken upon waking; the regimen simply resumes at the next designated nighttime dosing slot.

---

Gittalun is intended for short-term use only. Continuous administration does not extend beyond two consecutive weeks without medical consultation. Furthermore, the dose is only taken when the user can commit to a full night’s sleep of 7 to 8 hours to ensure appropriate use.

Gittalun: Recent Clinical Evidence

Gittalun is a brand name for the active compound doxylamine succinate, which is classified as an ethanolamine-based antihistamine. Research indicates that doxylamine succinate is used primarily for the short-term management of sleep difficulties. It has also been historically used in combination with other compounds for the management of nausea and vomiting, particularly during pregnancy, as studied in clinical literature.

---

Efficacy and Study Outcomes

Clinical trials examining the use of doxylamine succinate for transient insomnia have generally observed a reduction in the time required to fall asleep, as well as an increase in the total duration of sleep among adult participants compared to placebo. It is noted for its pronounced sedative property, which contributes to its use as a sleep aid. Study outcomes regarding its efficacy typically focus on these measured differences in sleep latency and total sleep time.

---

Safety and Tolerability Profile

As a first-generation antihistamine, the safety profile of doxylamine succinate is characterized by common potential side effects, with drowsiness and dry mouth being frequently reported in studies. Other reported side effects may include dizziness or confusion. Due to the sedative effects, caution is advised concerning activities that require mental alertness. Serious, though rare, complications observed in case reports have included muscle damage (rhabdomyolysis) with possible subsequent kidney function impairment in situations of misuse or high-dose intoxication.

Common Observed Effects	Rare, Serious Observed Effects
Drowsiness, Dry Mouth	Seizures, Tachycardia, Rhabdomyolysis

The evidence supports its use for temporary sleep difficulties, and its profile has been established over decades of use and study.

Common questions about Gittalun (FAQ)

Q: How long does it usually take to feel any effects from Gittalun?

Official administration guidelines advise taking Gittalun approximately 30 minutes before the intended time of going to bed. This timing is intended to ensure the drug’s action aligns with the necessary onset of sleep, as described in administration guidelines. The purpose of this required timing is to facilitate the temporary sleep-aid effect.

Q: Can Gittalun cause changes in mood or sleep patterns?

Official documents report that adverse reactions can include more than just drowsiness (somnolence). The medicine is associated with documented effects such as excitement, nervousness, and in rare instances, paradoxical central nervous system stimulation. These effects are linked to central nervous system activity, which can result in altered sleep patterns, such as agitation or insomnia, as documented in safety information.

Q: Is Gittalun classified as a controlled substance?

No, Gittalun is not classified as a controlled substance. Official FDA DailyMed documents specify that the active ingredient, doxylamine succinate, is designated with a DEA Schedule of None. This means it is regulated differently from medications classified as Schedule I, II, III, IV, or V.

Q: Do I need to change my diet while I am taking Gittalun?

Official regulatory information does not require a change to your general diet while using this medicine. The tablet can generally be managed with or without food as part of its administration protocol. Restrictions focus specifically on avoiding alcohol and other medications that may increase drowsiness, rather than advising broad dietary changes.

Q: Is Gittalun a generic medicine or a brand-only medicine?

Gittalun is the brand name for the active ingredient doxylamine succinate. Regulatory documents confirm that the drug substance itself is available in many countries under various generic and brand names as an over-the-counter (OTC) medicine for human use.

Q: What does the term ‘contraindication’ mean in relation to Gittalun?

The term contraindication is used in official regulatory documents to refer to a specific condition or factor that makes using the medicine prohibited. It means that use is prohibited in the presence of that condition or factor due to the potential for risk.

Q: Has Gittalun been approved by major regulatory bodies like the FDA or EMA?

Yes, the active ingredient in Gittalun, doxylamine succinate, is widely recognized by official health bodies. The FDA recognizes it under an Abbreviated New Drug Application status and accepts it as an over-the-counter nighttime sleep aid. Its use is also referenced in drug documentation from other major international health authorities.

Q: How long does Gittalun stay in your system after it is stopped?

According to official clinical pharmacology data, the active substance, doxylamine, is cleared relatively quickly. It has an approximate elimination half-life of around 10 hours in healthy adults. This half-life is the time it takes for the concentration of the drug in the body to be reduced by half.

Q: Can Gittalun affect the results of routine blood tests?

Yes, official warnings and precautions note that the medicine may interfere with certain lab results. This includes potentially false positive results in some urine screening tests for substances like methadone, opiates, and PCP. It is also documented to suppress the results of skin allergy tests.

Q: What have official sources said about stopping Gittalun use?

Regulatory documents advise that Gittalun should only be used for the short-term management of sleep difficulty. If a user finds that their sleeplessness persists continuously for more than two weeks, official guidance advises that the user should stop use and consult a healthcare professional. Use beyond this duration is constrained by regulatory limits.

Q: Is Gittalun available in different strengths or formulations?

For its primary purpose as a sleep aid, the medication is generally formulated as the 25 mg oral tablet. However, official information shows the active ingredient is also used in combination with other substances and in different strengths for other health purposes, such as nausea management.

Q: Is there a risk of dependence or addiction associated with Gittalun?

Regulatory labeling manages potential risks by explicitly setting an upper limit on continuous use. The official protocol limits use to a short-term maximum of two consecutive weeks. This time constraint is established to manage potential risks related to prolonged use, as detailed in the official safety profile.

Q: Is Gittalun used in countries outside of the United States?

Yes, the active ingredient, doxylamine succinate, is referenced in official drug documentation from multiple international health authorities. This includes bodies such as the European Medicines Agency (EMA), the Therapeutic Goods Administration (TGA) in Australia, and Health Canada.

Q: What does 'off-label' mean in a medical context?

According to official guidance, off-label use occurs when a medicine is administered for a purpose that is not specifically reviewed and approved by the relevant government drug authority. The primary approved uses are the only ones described in the official patient information.

Q: Can I take Gittalun if I have a history of heart problems?

The official safety profile advises caution for patients who have pre-existing severe cardiovascular disorders. This caution is due to the drug's classification as an anticholinergic agent, which can influence the cardiovascular system. Eligibility for use by individuals with pre-existing conditions is determined based on consultation with a healthcare professional.

Q: Does Gittalun have an effect on blood pressure or heart rate?

Official documents list that the active ingredient has been associated with tachycardia, which is an increased heart rate, as a reported adverse reaction. Official labels do not commonly list changes in blood pressure as an expected adverse effect.

Q: What are the general signs of an allergic reaction to Gittalun?

Official patient counseling information describes that symptoms of a serious allergic reaction (hypersensitivity) may include severe signs. These signs include skin rash, itching, hives, swelling of the face, lips, tongue, or throat, or sudden eye pain.

Q: Is Gittalun considered a new medication or has it been available for a while?

The medicine is not considered new; its active ingredient is categorized as a first-generation antihistamine. Official evidence indicates that its use and safety profile have been established and studied over a period of decades.

Q: Why is a specific lab test sometimes required before starting Gittalun?

Regulatory documents advise caution for patients with pre-existing Hepatic (liver) or Renal (kidney) Impairment. This caution advises that healthcare professionals may need to assess a patient’s organ function using specific lab tests to determine eligibility before use.

Q: How does Gittalun compare to older, established treatments for the same condition?

Gittalun belongs to the class of First-Generation H1 Receptor Antagonists. This class of drugs, which are ethanolamine derivatives, are chemically distinct from other sleep aids. Official documents note this drug class is clinically recognized for its pronounced sedative properties that aid in initiating sleep.

How to Store and Dispose of Gittalun

Official regulatory labeling dictates specific conditions for storing and disposing of Gittalun (Doxylamine succinate) tablets to maintain product stability and ensure public safety.

Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F).
Packaging	Retain in the original container or sealed blister packaging until use. Do not use if the seal or blister is broken.
Safety	The medication must be kept out of the reach of children.

Disposal Instructions

Unused or expired Gittalun should be disposed of promptly and safely. The recommended method is to use a drug take-back program or an authorized collection site. If a take-back program is unavailable, official guidance recommends mixing the tablets with an undesirable substance, such as dirt or used coffee grounds, placing the mixture in a sealed bag or container, and discarding it in the household trash. Gittalun is not on the list of medicines recommended for flushing down the toilet.